Blackstone Inc
SABS icon

Blackstone Inc’s SAB Biotherapeutics SABS Stock Holding History

Blackstone Inc’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-860,170
Closed -$3.29M – 653
2026
Q1 		$3.29M Sell
860,170
-1,283,415
-60% -$5.12M 0.01% 158
2025
Q4 		$8.02M Buy
+2,143,585
New +$7.05M 0.03% 105

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Blackstone Inc's SABS Position: Q2 2026 in Review

Blackstone Inc sold out of SAB Biotherapeutics (SABS) in Q2 2026, closing a stake of 860,170 shares — an estimated $3.29M sold.

Blackstone Inc first reported a position in SABS in Q4 2025 and held it in 2 quarters. The position peaked at $8.02M in Q4 2025. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Blackstone Inc reported no remaining SAB Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Blackstone Inc sold 860,170 SAB Biotherapeutics shares in Q2 2026, an estimated $3.29M.
  • Blackstone Inc first reported a position in SAB Biotherapeutics in Q4 2025 and held it in 2 quarters.
  • Blackstone Inc's SAB Biotherapeutics position peaked at $8.02M in Q4 2025.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.